| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHSURG.1995.01430010045009 |
| P698 | PubMed publication ID | 7802575 |
| P2093 | author name string | Vrouenraets BC | |
| Eggermont AM | |||
| Kroon BB | |||
| Franklin HR | |||
| van Geel BN | |||
| Klaase JM | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 43-47 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Archives of Surgery | Q15764793 |
| P1476 | title | Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions | |
| P478 | volume | 130 |
| Q50709661 | Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. |
| Q36894652 | Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations |
| Q44767313 | Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma |
| Q34020065 | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma |
| Q37180078 | Estimating the population burden of lymphedema |
| Q46118717 | Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients |
| Q36514467 | Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system |
| Q38836705 | Isolated limb perfusion in Merkel cell carcinoma offers high rate of complete response and durable local-regional control: Systematic review and institutional experience |
| Q38178220 | Isolated limb perfusion with melphalan for melanoma |
| Q35880947 | Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation |
| Q79080814 | Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities |
| Q74128065 | Isolated limb perfusion: is it a useful technique or a futile last gasp? |
| Q33955599 | Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases. |
| Q44972174 | Management of cutaneous melanoma M0: state of the art and trends |
| Q79252893 | Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion |
| Q41565231 | Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma |
| Q26852841 | Omental flap for treatment of long standing lymphoedema of the lower limb: can it end the suffering? Report of four cases with review of literatures |
| Q33209414 | One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases |
| Q46569856 | Outcomes following isolated limb infusion for melanoma. A 14-year experience |
| Q45959753 | Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. |
| Q37307175 | Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion |
| Q34964496 | Surgical approaches to malignant melanoma. Practical guidelines |
| Q36420187 | The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft |
| Q37130257 | Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma |
| Q39801051 | Treatment of cutaneous melanoma: current approaches and future prospects. |
Search more.